source
- Repligen strikes $1.5B BioLife buyout to bag cell therapy product pharmas rely onTop-selling cell therapies from BMS, J&J and Gilead depend on a BioLife product, positioning Repligen to use the takeover to increase its exposure to the modality.BioSpace · 7d ago↗ source
- 6 companies hiring in Cambridge nowLooking for a biopharma job in Cambridge? Roles posted on BioSpace have more than doubled compared to last year.BioSpace · 7d ago↗ source
- STAT+: Pharmalittle: We’re reading about Trump’s plan for tariffs on generics, a Merck and Gilead HIV pill, and morePresident Trump plans to impose tariffs on imported generic medicines, his latest threat aimed at bringing pharmaceutical manufacturing back to the U.S.STAT · 7d ago